Garvan Institute of Medical Research installs Southern Hemisphere's first Element AVITI

TrendBio, a leading supplier of medical research instruments and consumables in Australia and New Zealand, today announced a successful installation of the Element Biosciences AVITI™ System at the Garvan Institute of Medical Research, one of Australia’s premier medical research institutes. Addition of the Element AVITI expands Garvan’s commercial genome sequencing services to offer both short and synthetic long-read capabilities on a single platform while making sequencing flexible, highly accurate and affordable.

"We are excited to have acquired the first Element AVITI sequencer within the Southern Hemisphere. This cutting-edge technology signifies a notable milestone in the sequencing landscape and further strengthens the Institute’s leading genomic research capability. The Garvan Institute is proud to pioneer Element AVITI sequencing capabilities with investigators within our research precinct and across Australasia for a wide array of research applications," says Dr Jim Blackburn, Head of the Genomics Platform at Garvan.

Element’s AVITI System is an innovative benchtop sequencer offering an unrivaled combination of performance, cost, and flexibility. The system has a twin flow cell design and individually addressable lanes, allowing the flexibility for operating two separate sequencing runs in one system. The operating software has a tunable read throughput control, allowing users more run flexibility for their data output ranges from 50 to 600 Gb and 100 million to 2 billion reads depending on the selection of the read lengths and flow cell.

 

Together with Element’s proprietary avidity base chemistry (ABC), the AVITI enables exceptional accuracy (>90% >Q30) and reduced reagent consumption, delivering higher quality data and more cost-effective sequencing options compared to other sequencing systems.

“This milestone of the first AVITI installation in the Southern Hemisphere underscores Element’s commitment to serving and empowering customers throughout the world,” said Yaron Hakak, PhD, Senior Vice President of Corporate and Business Development at Element Biosciences. “We are thrilled to help Garvan in its mission to advance research to improve human health using the power of genomic information.”

Trent Warburton, Managing Director of TrendBio, added. “Garvan is leading the way with the installation of this state-of-the art technology. We are proud to support the expansion of Garvan's sequencing services. Making sequencing accessible and affordable will significantly advance genomic sequencing. We look forward to seeing Garvan utilise this technology to advance their research outcomes”.

Media enquires:
Joyee Yeung
1300 720 574
This email address is being protected from spambots. You need JavaScript enabled to view it.